The influence of the gut microbiome on ovarian aging

ABSTRACT Ovarian aging occurs prior to the aging of other organ systems and acts as the pacemaker of the aging process of multiple organs. As life expectancy has increased, preventing ovarian aging has become an essential goal for promoting extended reproductive function and improving bone and genitourinary conditions related to ovarian aging in women. An improved understanding of ovarian aging may ultimately provide tools for the prediction and mitigation of this process. Recent studies have suggested a connection between ovarian aging and the gut microbiota, and alterations in the composition and functional profile of the gut microbiota have profound consequences on ovarian function. The interaction between the gut microbiota and the ovaries is bidirectional. In this review, we examine current knowledge on ovary-gut microbiota crosstalk and further discuss the potential role of gut microbiota in anti-aging interventions. Microbiota-based manipulation is an appealing approach that may offer new therapeutic strategies to delay or reverse ovarian aging.


Introduction
The gut microbiota, which is the second genome of the human body, plays an important role in human health and pathogenesis.The gut microbiota is a complex symbiotic ecosystem, and imbalances in the gut microbiota have been widely reported in a range of common chronic diseases, such as type 2 diabetes, cardiometabolic diseases and metabolic liver diseases. 1ounting evidence has confirmed that there is a bidirectional relationship between the gut and numerous crucial organs of the host, in which the microbiota serves as a regulator. 2,3ignificant changes in the identities of dominant microorganisms, bacterial diversity, and functional features have been uncovered in human aging and age-related diseases. 4,5A recent study showed the existence of multiple "clocks" within the body: organs/systems age at different rates, and the aging rate of specific organs or systems correlates with that of the gut microbiome. 6Consequently, individuals may present with different health or disease states.Gut microbial features can be used to predict healthy aging or mortality in elderly individuals. 7,8nterestingly, experiments on mice demonstrated that transplantation of aged donor microbiota accelerates specific processes of age-associated brain degeneration in the recipient, and conversely, transplantation of young donor microbiota can reverse this condition. 9,10It has been suggested that the gut microbiota could serve as a potential therapeutic target for new anti-aging interventions. 5varian aging refers to the gradual decline in ovarian function with age.It is characterized by the gradual deterioration in oocyte quantity and quality, accompanied by menstrual cycle irregularity, infertility and finally, the cessation of menses. 11The ovary experiences a different lifespan from other organs.Recently, multiomics profiling identified a significant acceleration in female biological aging around the third and fifth decades of life, which coincided with the time points of fertility decline and menopausal status. 12hus, ovarian aging is considered the pacemaker of aging in the female body, driving the aging of multiple organs. 13The levels of sex hormones, including follicle-stimulating hormone (FSH), luteinizing hormone (LH) and anti-Müllerian hormone (AMH), were highly correlated with several other aging clocks. 12As life expectancy increases worldwide, ovarian aging will gradually become a major health problem for women. 14varian aging is an extremely complex process with causes that have not yet been fully clarified.Growing evidence shows that there is a link between the gut microbiota and ovarian function, 15 and the gut microbiota-ovary axis contributes to follicular development. 16In this review, we aim to synthesize different aspects of ovarymicrobiota crosstalk and provide meaningful conclusions (Figure 1).We also try to explain the potential role of the microbiota in some antiaging approaches.

The gut microbiota and natural ovarian aging
Menopause is the hallmark event of natural ovarian aging.Natural menopause, which mostly occurs between the ages of 49 and 52 years, is diagnosed retrospectively after a 12-month cessation of spontaneous menses without pathological causes. 17As the finite stores of ovarian follicles are depleted and the remaining follicles lose their sensitivity to gonadotropins, the follicles stop developing and secreting the ovarian hormones estrogen and progesterone. 18stradiol (E2) levels only decrease relatively late during the process of perimenopausal transition. 11owever, a dramatic decline in plasma E2 levels occurs during the final menstrual cycle, and afterward, the postmenopausal ovaries stop synthesizing E2. 19 It is known that the gut microbiome is one of the important regulators of circulating estrogens. 20Gut microbial β-glucuronidase (gmGUS) can transform estrogen from deactivated forms to active forms and further affect estrogen levels in the host. 21,22Gut microbiota dysbiosis and lower microbial diversity result in a reduction in gmGUS and alterations in systemic estrogens. 15Gut bacteria, in turn, are also influenced by estrogen.It has been reported that the relative abundances of two bacterial taxa, namely, the Gammaproteobacteria class and an unknown family from Mixococcales, were positively correlated with E2 levels, and the abundance of the family Prevotellaceae was negatively correlated with E2 levels. 23,24Furthermore, estrogen or estrogen-like compounds exert microbiome-modulating effects and maintain gut epithelial barrier integrity in mice with metabolic syndrome. 25upplementation with estrogen-like foods such as soy isoflavones augments the abundances of the genera Bifidobacterium and Eubacterium while restraining the genera Lactobacillus and unclassified Clostridiaceae in postmenopausal women. 26nder certain pathological conditions, dysbiosis of the gut microbiota and elevated gmGUS activity may contribute to the development of estrogendriven diseases and menopause-related disorders by participating in the circulation or activation of endogenous and exogenous estrogen-like compounds. 21enopausal status is known to affect the gut microbiota.Differences in the composition and the functional profile of the gut microbiota between women of different menopausal statuses have already been reported as described below.A total of 90 differentially abundant taxa between premenopausal (n = 44) and postmenopausal women (n = 45) were observed, and the pyrimidine and one-carbon pools associated with the folate pathways were enriched in premenopausal women compared with postmenopausal women. 27he genus Roseburia was identified as the most remarkable bacterial taxon to discriminate between premenopausal (n = 17) and postmenopausal groups (n = 20), and higher propanoate and butanoate metabolism in premenopausal women was observed. 23In contrast, Zhao et al. demonstrated that the alpha diversity of microbiomes in postmenopausal women (n = 24) was significantly lower than that in premenopausal women (n = 24), the abundances of the phylum Firmicutes and the genus Roseburia were low, the abundances of the phylum Bacteroidetes and the toluene-producing genus Tolumonas were enriched in postmenopausal women, and homocysteine synthesis-related processes were activated in postmenopausal women. 28Other microbes, such as the genera A. odoratum and B. cholerae, were also enriched in postmenopausal women (n = 90) compared with premenopausal women (n = 66). 24Remarkably, Firmicutes and Bacteroidetes are dominant groups of beneficial bacteria in the human gut 29 and Roseburia is a butyrate-producing bacteria. 30,31lthough taxa across studies varied, it might be attributed to the different study populations, sample sizes or methods.
In an animal model, alterations in the gut microbiota induced by ovarian aging were also described.4-Vinylcyclohexene diepoxide (VCD), an occupational chemical that directly kills primordial and primary ovarian follicles of the ovary but shows no toxicity toward extraovarian tissue, induces ovarian aging analogous to natural ovarian aging. 32searchers determined that there were significant differences in both the alpha and beta diversity between the mice in the VCD group and the control group. 33The levels of several genera, including Helicobacter, Odoribacter, and Alistipes, were lower, and Clostridium XIVa, Barnesiella, Bacteroides, and Mucispirillum were higher among the dominant microbiota of the VCD group. 33Studies in Drosophila revealed that the intestinal epithelium deteriorates as females age, which leads to high microbiota loads, barrier impairment, and decreased lifespan. 34,35The steroid hormone ecdysone, produced by active ovaries of the fly, could stimulate the division and expansion of intestinal stem cells and enhance their reproductive output. 36o further probe the more complicated and deeper causal linkage between the gut microbiota and natural ovarian aging, fecal microbiota transplantation (FMT) was applied to naturally aging mice.Aged mice (42 weeks old) treated with FMT from young donors (5 weeks old) presented a "young animal-like phenotype" in the gut microbiome, and follicular atresia and apoptosis were reduced to improve the fertility of aged mice. 37These ovarian aging-delay effects might be explained by improving the inflammatory status and immune microenvironment. 37,38Substantial evidence in aged zebrafish also demonstrated the effect of the young microbiota on reproductive modulation.FMT from young donors to aged zebrafish could counteract the adverse effects of subsequent exposure to toxic pollutants, potently reduce the levels of membrane-bound progestin receptor transcripts, promote the progression of oogenesis, and reduce the rate of malformations caused by toxic pollutants, and their offspring presented a stronger locomotor capability and swam much faster. 39verall, maintenance of a "youthful" gut microbiota during ovarian aging may limit ovarian senescence and provide additional benefits.

The gut microbiota and premature ovarian insufficiency
Rather than natural ovarian aging, some women in the population experience a premature decline in ovarian function, that is, premature ovarian insufficiency (POI). 40POI is a clinical syndrome defined by exhaustion of normal ovarian activity in patients younger than 40 years, which presents as a menstrual disorder (amenorrhea or oligomenorrhea) with elevated gonadotropin levels and low E2 levels. 41The estimated global prevalence is as high as 3.7%, while 0.1% of women aged less than 30 and 0.01% of women aged less than 20 present with the condition. 424][45] POI is a highly heterogeneous condition, with 70 to 90% of POI cases having unknown causes in addition to known genetic, autoimmune, infectious, and iatrogenic factors, that is idiopathic POI. 42Recently, mounting evidence has suggested that gut microbiota dysbiosis is associated with POI.In this section, we review the current research linking gut microbiota and POI, focusing on idiopathic POI, iatrogenic POI and POI-driven diseases.

Idiopathic POI
It has been noted that there was a reduction in beta diversity in patients with POI. 46At the phylum level, higher Bacteroides and lower Firmicutes abundances were observed in POI patients, while higher Butyricimonas, Dorea, Lachnobacterium, and Sutterella and lower Bulleidia and Faecalibacterium abundances at the genus level were observed in women with POI (n = 35) than in healthy women (n = 18). 47These microbial changes were correlated with the levels of FSH, LH, E2, and AMH and the FSH/LH ratio. 47In addition, decreases in the abundances of the genera Eggerthella and Staphylococcus and increases in the abundances of the genera Comamonas and Barnesiella were observed in POI patients (n = 10) relative to controls (n = 10). 46esearchers have also revealed positive associations between Eggerthella and several serum metabolites. 46Although POI shares similar clinical manifestations with natural ovarian aging, few studies have reported differences in the gut microbiota between them.
Hormone replacement therapy (HRT) is the primary recommended treatment given to women with POI both for symptom management and disease prevention. 40Jiang et al. determined that the alterations in beta diversity, relative abundance of the genus Eggerthella, serum metabolites, and E2 and progesterone hormone levels related to POI were significantly reversed after HRT implementation, 46 which further validated the interaction between estrogen and gut microbiota.Animal experiments confirmed that E. lenta gavage induced ovarian fibrosis in mice and that estrogen treatment alleviated ovarian fibrosis. 46Despite the potential linkage between POI and the gut microbiota, the causal nature of this relationship still needs to be deeply investigated.
Taken together, these results show that gut microbiota dysbiosis, such as disturbance of core microbiota (Lachnoclostridium and Bacteroides), short-chain fatty acid (SCFA) producers (Bacteroides and Faecalibacterium) and an increase in opportunistic pathogenic bacteria (Eggerthella), may be involved in the pathology of POI, and the reversal of gut microbiota may be a new strategy for ovary preservation to some extent.

Iatrogenic POI
As noted above, most POI cases are idiopathic.][50] Many medical factors can damage ovarian function, such as pelvic radiotherapy, chemotherapy and surgery, in tumor patients, which can lead to premature decline or even total loss of ovarian function. 513][54][55] Patients who have undergone ovarian surgery, especially laparoscopic surgery, are candidates for iatrogenic POI. 48Bone loss and genitourinary atrophy are two major challenges faced by many young cancer patients and postsurgical women due to iatrogenic ovarian injury, which seriously impacts their overall quality of life. 50 study profiled and analyzed the changes in gut microbiota in ovarian cancer patients who underwent different anticancer treatments and found that postsurgery samples exhibited a significant decrease in the abundances of the phyla Bacteroidetes and Firmicutes and a significant increase in the abundance of the phylum Proteobacteria compared with presurgery samples; however, after-chemotherapy samples exhibited significantly increased abundances of the phyla Bacteroidetes and Firmicutes and a decreased abundance of the phylum Proteobacteria compared with before. 564][55][56][57][58][59] Therefore, we focused on mouse ovariectomy studies to demonstrate the relationship and mechanism of the gut microbiome and iatrogenic menopause.Animal studies have shown that changes in the gut microbiota are associated with iatrogenic ovarian aging and associated relevant adverse outcomes.
Many studies based on an ovariectomized (OVX) mouse model have revealed that the gut microbiota could be affected by iatrogenic menopause. 60Significant differences in beta diversity [61][62][63][64] and alpha diversity 62 have been observed between the gut microbiota of the OVX group and the sham group.6][67][68] At the genus level, the abundance of the predominant genera in the sham group decreased significantly in the OVX group (87% vs. 29%). 62In contrast, lower-abundance genera in the sham group were importantly enriched in the OVX group (<5% vs. 63%). 62Zhang et al. identified four key significant genera in OVX rats: Incertae_Sedis, Anaerovorax, Anaerotruncus and Helicobacter. 63Furthermore, the OVX group exhibited apparent weight gain, 65 intestinal barrier impairment 61 , bone loss 65,66 and vaginal atrophy. 64The gut microbiota is indispensable for OVX-induced osteoclast differentiation, and germ-free (GF) animals were protected against osteoporosis induced by OVX.The Firmicutes Bacteroidetes phylum and the Firmicutes/ Bacteroidetes ratio were critical in osteoclast differentiation, and supplementation with the probiotic Lactobacillus salivarius LI01 from the Firmicutes phylum prevented OVX-induced osteoporosis in mice. 67FMT from ovary-intact mice inhibited the gut microbiota changes and weight gain induced by OVX, suppressed the release of proosteoclastogenic cytokines, increased fecal SCFA levels (mainly acetic acid and propionic acid), reduced intestinal permeability and ultimately prevented OVX-induced bone loss. 65Surprisingly, Huang et al. showed that FMT from ovary-intact fecund females changed the gut microbiota and significantly alleviated vaginal epithelial atrophy in OVX mice. 64In general, FMT might act as a promising target for the prevention and treatment of iatrogenic ovarian aging-related consequences (Figure 2).

Antiaging drugs
To date, no clinically feasible techniques are available to either delay or reverse ovarian dysfunction associated with advanced age. 69][70] Although no study has directly explored the relationship among these antiaging drugs, ovarian function and gut microbiota, some indirect evidence has shown that the beneficial effects of these drugs may be associated with gut microbes.As shown in Table 1, these drugs may work through intestinal microbes. 102

CoQ10
CoQ10 is a fat-soluble, vitamin-like benzoquinone compound, plays a critical role in cellular energy production and functions as an antioxidant in its reduced form. 69The synthesis of CoQ10 appears to decrease with age, which coincided with the time point of fertility and oocyte quality decline. 103retreatment with CoQ10 during the fertility treatment improved ovarian response and the quality of embryo in young patient with diminished ovarian reserve. 104CoQ10 treatment in mice not only preserved the ovarian follicle pool but also promoted ovulation of gametes capable of supporting normal development. 68,103Dietary CoQ10 supplementation also had beneficial effects on the reproductive variables of aged hens 105 gestating sows with high parity 91 and red tilapia. 82However, in women with infertility undergoing assisted reproductive technology procedures, CoQ10 increased clinical pregnancy but showed no effect on live birth or miscarriage rates. 106CoQ10 also has an impact on the gut microbiota and the subsequent biomarkers it produces.Three-week of administration of CoQ10 resulted in 2.4 times and 7.5 times increase in the relative abundance of Ruminococcus and Lachnospiraceae AC 2044 groups, respectively, as well as a 1.26-fold increase in butyrate. 77

Melatonin
Melatonin is an indoleamine produced by all cells, especially those in the pineal gland. 76As a powerful antioxidant, melatonin has been shown to delay the decline in fertility in female animals. 71,73Oxidative stress (OS) is considered a key factor in ovarian aging that accelerates follicle loss and atresia, 74 along with significant gut microbiota dysbiosis 73,107 while melatonin reverses OSinduced phenotypes and improves gut microbiota communities. 75Melatonin treatments in mice not only significantly increased the number and quality of oocytes but also led to more blastocyst generation after in vitro fertilization and larger litter sizes than those in the controls. 73Hao et al. identified that melatonin might increase the levels of E2 and LH as well as the levels of immunoglobulin and the numbers of growing follicles in aged laying hens. 71elatonin pretreatment reduced the Firmicutes abundance and the Firmicutes/Bacteroidetes ratio and increased the content of Bacteroidetes at the phylum level. 108Additionally, oral melatonin supplementation significantly reversed gut microbiota dysbiosis induced by a high-fat diet (HFD), including the decreased alpha diversity of the intestinal microbiota, the decreased relative abundances of the genera Bacteroides and Alistipes, and the increased relative abundances of the order Lactobacillales and the genus Lactobacillus. 109The marked correlation between acetic acid production and the relative abundances of the genera Bacteroides and Alistipes after FMT from melatonin-treated mice indicated that gut microbiota reprogramming might be the potential mechanism of melatonin treatment. 109

Nmn
NMN is another promising anti-ovarian aging drug.The loss of oocyte quality with reproductive aging accompanies declining levels of nicotinamide adenine dinucleotide (NAD+), 81 and as an intermediate of NAD+ biosynthesis, NAD+ can be compensated by NMN supplementation to play a role in delaying ovarian aging. 107Twenty-week oral administration of NMN to middle-aged mice improved the estrous cycle condition, increased the number of follicles at different stages and the corpora lutea and serum FSH, and enhanced mitochondrial biogenesis, autophagy, and protease activity of granulosa cells (GCs) compared with the control treatment. 110In HFD-induced POI mice, NMN administration reduced ovarian inflammation and the adipose size of abdominal fat tissue and improved oocyte quality. 70NMN treatment increased the abundance of butyrateproducing bacterial genera, such as Ruminococcae_UCG-014, Prevotellaceae_NK3B31_group and the probiotic Akkermansia muciniphila, while decreasing the abundances of several harmful bacterial genera, such as Oscillibacter and Bilophila. 78NMN also reduced intestinal mucosal impairment and maintained mucosal barrier integrity. 78

Resveratrol
Resveratrol, a natural polyphenol, potentially delays ovarian aging and protects against ageassociated infertility 79,111,112 and is capable of restoring the microbiota composition and reversing intestinal dysbiosis. 83A study revealed that resveratrol ameliorated the oxidative stressinduced reduction in egg-laying rate and serum hormone level changes, as well as gut microbiota dysbiosis, and elevated the concentrations of the main SCFAs in laying hens. 84This study directly proved that resveratrol modulated ovarian function through intestinal microbes.Enrichment of Bacteroides, Lachnospiraceae_NK4A136_group, Blautia, Lachnoclostridium, Parabacteroides and Ruminiclostridium_9, collectively referred to as the resveratrol-microbiota, displayed anti-obesity functions. 113

Rapamycin
The mammalian target of rapamycin (mTOR) signaling pathway exerts a vital role in folliculogenesis in female germline cells. 114Activation of the AKT/ mTOR signaling pathway in POI patients has been reported. 115Suppressing mTOR signaling in HFDinduced POI mice reversed follicle loss and extended the ovarian lifespan. 116Rapamycin is a natural macrolide compound initially segregated from bacteria and serves as a TOR signaling inhibitor. 85Rapamycin treatment increased ovarian reserve 86 and prolonged ovarian lifespan with oocyte quality improvement, especially in aged mice. 87In a cyclophosphamide-induced POI model, rapamycin prevented primordial follicle loss and protected the ovarian reserve. 88 significant increase in the levels of segmented filamentous bacteria (Candidatus Arthromitus sp.) in rapamycin-treated mice was observed.89 However, although rapamycin rescued intestinal barrier dysfunction and increased microbial loads in Drosophila, its antiaging effects seemed to be independent of the gut microbiota.92

Nac
NAC is synthesized to help stimulate the synthesis of glutathione to exert antioxidant effects. 94A study conducted in mice proposed that the administration of NAC could improve the quality of preimplantation oocytes and increased the total blastocyst cell number and litter sizes, thus delaying the fertility decline with reproductive aging. 96NAC alleviated gut dysbiosis in HFD-fed mice by promoting the growth of several beneficial bacteria and affect the metabolic pathways of intestinal bacteria. 97,98In general, evidence on the effects of NAC treatment on reproductive aging and gut microbiota are rare and fertility-related researches to assess the effects of NAC administration are needed.

Antiaging diet
In addition to antiaging drugs, antiaging diets seem to be a more popular option, of which caloric restriction (CR) is currently regarded as the most reproducible strategy. 90,95CR refers to reducing energy intake without incurring malnutrition or a lack of essential nutrients. 93,117As a dominant paradigm for antiaging diets, its life-extending effect has been widely acknowledged. 99Over the past decades, attention has been given to the effect of CR on reproduction and gut microbiota (Tables 2 and 3).
1][142][143] CR was associated with weight loss, reduced abdominal visceral fat accumulation, and increased insulin sensitivity. 86,144Consequently, imposed ovarian aging-delay effects through the inhibition of follicle loss and preservation of the follicle pool.Unlike in control rodents, rodents that underwent CR treatment showed significantly increased numbers of primordial follicles and inhibited development of follicles at different stages 86,118,120,122,123,145 as well as an increased ratio of estrogen to androgen receptors. 119Ten weeks of CR feeding decreased serum LH, FSH, and estrogen levels. 120CR exerted a similar effect in HFD-induced POI mice. 116The p53 downregulation induced by CR may inhibit follicle atresia because of its effects on the cell cycle and apoptosis. 145CR can also rescue agerelated microbiota alterations observed in aged female mice. 121Three months of 34% CR helped to attain significant weight loss, and decreased waist circumference coincided with changes in five bacterial genera (Subdoligranulum, Collinsella, Parabacteroides, Alistipes, and Bacteroides). 146Thirty days of 40% CR in mice increased the abundances of Lactobacillaceae, Erysipelotrichaceae, Bacteroidaceae and Verrucomicrobiaceae and decreased the abundance of Firmicutes at the family level, improved glucose metabolism, fat browning, and cold tolerance and reduced LPS-binding protein and circulating LPS levels. 129In addition, severe CR decreased body fat deposition and improved glucose tolerance 125 but enriched Akkermansia which capable of foraging on host glycans and expensed Roseburia, Ruminococcus, and Eubacterium which specialized for the metabolism of plant polysaccharides in human feces. 147hronic inflammation is another common condition in aging 130 as well as in ovarian aging. 38nflammation might be one of the mechanisms contributing to reproductive aging.Lliberos et al. reported that the increase in the intraovarian percentage of B cells, CD4 + T cells and macrophages was consistent with the process of ovarian aging and that age-dependent overexpression of multiple proinflammatory cytokines, including IL-6, TNFα, and IL-1α/β, and the inflammasome genes NLRP3 and ASC was observed during reproductive aging. 148Inhibition of the NLRP3 inflammasome helps to prevent ovarian aging. 38The gut microbiota plays a vital role in the modulation of the inflammatory response. 149,150CR might delay immune senescence by shaping the gut microbiome.CR-microbiota transplantation increased alpha diversity and lowered the abundances of Clostridium ramosum, Hungatella hathewayi, and Alistipes obesi in recipients, and these CR-related microbiota reduced the levels of intestinal and hepatic effector memory CD8 + T cells, intestinal memory B cells, and hepatic effector memory CD4 + T cells. 125Another study discovered five other CR-related operational taxonomic units in obese women: Anaerostipes hadrus, Blautia sp., Agathobacter rectalis, Ruminococcus faecis within Ruminococcaceae, and Bifidobacterium sp.within the family Bifidobacteriaceae, and reduced systemic inflammation was found in obese women after CR. 151 Moreover, CR for 2 weeks dramatically reduced intestinal inflammation and increased the protective intestinal microbiota taxon Lactobacillus and the survival rate of 2-month-old female mice after lethal-dose methotrexate exposure. 124The increased Bifidobacterium and Lactobacillus levels induced by lifelong CR were inversely correlated with the levels of bile acids, including ChDxCA and secondary bile acids (DxCA/TDxCA and a ChDxCA derivative). 128The Lactobacillusdominant microbial community promoted by CR decreased the levels of systemic microbial antigens and inflammatory markers. 126Based on the discovery of several molecular pathways associated with CR mentioned above, CR might be a possible strategy to improve inflammation and possibly promote obesity-related infertility and reproductive span.Notably, these anti-aging interventions described above either examined the effects on the gut microbiome or ovarian function, and few studies except one 84 speculated on anti-aging drugs, the gut microbiome, and ovarian function simultaneously.Thus, the current evidence that the gut microbiome involved in the mechanism of treatment affects ovarian function is fragmented and scattered, which is also a limitation of this review.There is still a large gap in how these antiaging interventions interact between the gut microbiota and ovarian function.Thus, more research focusing on the effects of these interventions on the gut microbiome and ovarian function is urgently needed to link the interaction of the three parts.

Conclusions
In conclusion, altered composition and function of the gut microbiota play an important role in the pathogenesis of reproductive aging.Experimental and clinical studies have uncovered the relationship between gut dysbiosis and follicle development, as well as a disturbed immune response.Results from FMT studies provide a new insight to anti-ovarian aging, that is the maintenance of youthful gut microbiota helps to preserve ovarian function and prevent ovarianrelated diseases.Microbiota-based intervention to delay or reserve ovarian aging is an appealing approach and may offer new therapeutic strategies for intestinal microbiota regulation to improve female fertility.
Furthermore, investigation of antiaging interventions such as antiaging drugs and CR may improve the gut microbial imbalance and promote a healthier intestinal ecological environment.However, evidence from the current scientific literature cannot offer direct conclusions regarding these measures.The majority of the relevant studies were conducted in animal models, which cannot simply apply to human beings.Therefore, future studies should shift from simple correlation analysis to large-scale cohort research and focus on the potential causes and underlying mechanisms to verify the beneficial effects of these interventions in ovarian aging.
Given the wide alterations in the gut microbiota composition and function throughout ovarian aging, it has been suggested that the gut microbiota may be suitable for deciphering the processes of expected and unexpected ovarian aging in women.Imbalance in the gut microbiota may lead to the progression of various ovarian aging-related conditions.Although ovarian aging is unavoidable, maintenance of a balanced gut microbiota is a potential way to delay ovarian aging and subsequent adverse outcomes.

Perspectives
Recent studies have achieved considerable progress in elucidating the roles of the gut microbiota in ovarian aging.However, it is still unclear whether gut microbial changes are the cause or consequence of ovarian aging, and the exact time point at which to modulate the gut microbiota to exert anti-ovarian aging effects remains unsolved.Understanding the relationship between the gut microbiota and ovarian aging is still relatively preliminary, the core mechanism needs to be further explored, and more high-quality evidence is urgently needed.Many factors may affect the gut microbiota, such as age, obesity, dietary pattern, antibiotic usage, and smoking, and these confounders need to be fully considered in future studies.Additionally, metagenomic analyses with a strain-level resolution are warranted because of the high variability of specific species and strains.
Based on the current scientific literature, we can only find some bacterial groups that are closely related to ovarian aging, and the current evidence is relatively scattered.The effects are likely achieved through a pleiotropic mechanism, one of which is an altered production of microbeassociated metabolites. 127The role and molecular mechanism of specific strains and their metabolites in follicle development are still uncertain and remain largely unexplored.Several studies have reported that both intestinal and serum metabolite disorders exist in POI samples, 46,152,153 and some metabolites may mediate the function of the hypothalamic-pituitary-ovary axis. 152,154ignificant correlations among SCFAs with follicular development and follicular fluid hormones were found. 16Supplementation with specific metabolites may be another choice for regulating ovarian function.Zhang, et al found that polyamine metabolite spermidine level was reduced in ovaries of aged mice and supplementation with spermidine promoted follicle development, rejuvenated oocyte quality and improved fertility rate of aged mice. 155And Guo, et al found that Branch chain amino acid (BCAA) insufficiency could lead to POI, and supplementation with BCAA ameliorated ovarian dysfunction from reactive oxygen speciesinduced POI in mice. 152Long-term NMN treatment led to significantly higher levels of bile acid-related metabolites. 78However, there are still a series of specific metabolites should be further identified and validated.In addition, follicular atresia is initiated with the apoptosis of GCs after birth. 156A study has indicated that the gut microbiota may participate in regulating ovarian follicular development via SCFAs affecting GC apoptosis. 16The effects of other certain metabolites to GC apoptosis are worthy exploring.
Furthermore, numerous studies have suggested that bacteriotherapy using three slightly different agents: probiotics, prebiotics, and synbiotics are promising for the prevention and treatment of human general aging and age-related disorders, 5,103,[157][158][159][160][161] in which Lactobacillus and bifidobacterium are the most commonly used, though the effects varied across studies, which depending on dosage, duration, and their components. 162Several clinical trials have demonstrated that the intake of a probiotic mixture decreasing inflammatory levels, increased the abundance of an anti-inflammatory commensal bacterium and improved cognitive function in older people. 80,131Additionally, studies have shown that some probiotic strains have beneficial effects on male reproductive dysfunction. 132,133upplementation of Lactobacillus and Bifidobacterium improved sperm motility and reduced rate of DNA fragmentation in males. 134upplementation with probiotics can restore serum testosterone levels and increased spermatogenesis in aging mice. 135However, the effects of the probiotics, prebiotics, and synbiotics on the ovarian aging are unclear, and more studies are required to prove whether they could be effective strategies to counteract ovarian aging.

Disclosure statement
No potential conflict of interest was reported by the author(s).insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: a report from the international late effects of childhood cancer guideline harmonization group in collaboration with the PanCareSurFup consortium.J Clin Oncol.2016;34 (28)

Figure 1 .
Figure 1.The physiologic succession of gut microbiota across natural ovarian aging.

Figure 2 .
Figure 2. FMT alter the gut microbiota and slow the progression of ovarian aging related diseases.

Table 1 .
Association among antiaging drugs, ovarian function and intestinal microbes.